重组促红细胞生成素对中重度创伤性脑损伤远期结局的影响
该研究为多中心促红细胞生成素治疗创伤性脑损伤试验(2010—2015年)的预先计划长期随访,共487例有生存数据,356例纳入随访,中位随访时间距损伤6年。EPO组与安慰剂组患者生存无差异(HR 0.73,95%CI 0.47-1.14,p=0.17)。以GOSE 5-8分定义的良好结局率EPO组110/175(63%) vs 安慰剂组100/181(55%),绝对风险差8%(95%CI 3-18%,p=0.14);按基线功能相对判定的滑动尺度良好结局绝对风险差12%(95%CI 2-22%,p=0.02)。按TBI严重程度、颅内占位病变、是否合并多发伤预设亚组均未见治疗效应异质性。结论认为EPO既未降低中重度TBI ICU患者远期总死亡率,也未改善功能结局,样本量有限使最终结论受限。
要点
- EPO组与安慰剂组远期生存无差异:HR 0.73(95%CI 0.47-1.14),p=0.17。
- GOSE 5-8分良好结局率EPO组63%(110/175) vs 安慰剂组55%(100/181),绝对风险差8%(95%CI 3-18%),p=0.14。
- 按基线功能相对判定的滑动尺度良好结局,EPO组绝对风险差12%(95%CI 2-22%),p=0.02。
- TBI严重程度(p=0.85)、颅内占位病变(p=0.48)、合并多发伤(p=0.08)均未见远期生存的治疗效应异质性。
- 功能结局亦未见治疗效应异质性;原文结论:样本量有限,难以对EPO用于TBI作出最终结论。
适用人群与场景
- 中重度创伤性脑损伤并在ICU治疗的患者,来自多中心促红细胞生成素治疗创伤性脑损伤试验(2010—2015年)。
- 原试验603例患者中487例有生存数据,356例纳入长期随访,中位随访时间距损伤6年。
诊断标准与关键阈值
- TBI严重程度采用国际预后与临床试验分析任务(International Mission for Prognosis and Analysis of Clinical Trials in TBI)模型分类。
- 功能结局采用格拉斯哥结局扩展量表(GOSE),5-8分定义为良好结局;另按基线功能相对判定良好结局(滑动尺度)。
研究设计与关键结果
- 研究类型为多中心促红细胞生成素治疗创伤性脑损伤试验的预先计划长期随访;原试验共603例,487例有生存数据,356例纳入随访,中位随访时间距损伤6年。
- 患者生存:EPO组 vs 安慰剂组HR 0.73(95%CI 0.47-1.14),p=0.17。
- 良好结局(GOSE 5-8分):EPO组110/175(63%) vs 安慰剂组100/181(55%),绝对风险差8%(95%CI 3-18%),p=0.14。
- 按基线功能相对判定的良好结局(滑动尺度):EPO组绝对风险差12%(95%CI 2-22%),p=0.02。
- 远期生存的治疗效应异质性:TBI严重程度p=0.85,颅内占位病变p=0.48,合并多发伤p=0.08。
- EPO对功能结局的效应亦未见治疗异质性。
证据类型、等级与局限
- 证据类型:多中心随机对照试验的预先计划长期随访。
- 局限:原文结论指出样本量有限,难以对EPO用于TBI作出最终结论。
对床旁实践的改变
- 原文结论:EPO既未降低中重度TBI ICU患者的远期总死亡率,也未改善功能结局。
- 原文结论:样本量有限,难以对EPO用于TBI作出最终结论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Recombinant erythropoietin (EPO) administered for traumatic brain injury (TBI) may increase short-term survival, but the long-term effect is unknown.
METHODS: We conducted a pre-planned long-term follow-up of patients in the multicentre erythropoietin in TBI trial (2010-2015). We invited survivors to follow-up and evaluated survival and functional outcome with the Glasgow Outcome Scale-Extended (GOSE) (categories 5-8 = good outcome), and secondly, with good outcome determined relative to baseline function (sliding scale). We used survival analysis to assess time to death and absolute risk differences (ARD) to assess favorable outcomes. We categorized TBI severity with the International Mission for Prognosis and Analysis of Clinical Trials in TBI model. Heterogeneity of treatment effects were assessed with interaction p-values based on the following a priori defined subgroups, the severity of TBI, and the presence of an intracranial mass lesion and multi-trauma in addition to TBI.
RESULTS: Of 603 patients in the original trial, 487 patients had survival data; 356 were included in the follow-up at a median of 6 years from injury. There was no difference between treatment groups for patient survival [EPO vs placebo hazard ratio (HR) (95% confidence interval (CI) 0.73 (0.47-1.14) p = 0.17]. Good outcome rates were 110/175 (63%) in the EPO group vs 100/181 (55%) in the placebo group (ARD 8%, 95% CI [Formula: see text] 3 to 18%, p = 0.14). When good outcome was determined relative to baseline risk, the EPO groups had better GOSE (sliding scale ARD 12%, 95% CI 2-22%, p = 0.02). When considering long-term patient survival, there was no evidence for heterogeneity of treatment effect (HTE) according to severity of TBI (p = 0.85), presence of an intracranial mass lesion (p = 0.48), or whether the patient had multi-trauma in addition to TBI (p = 0.08). Similarly, no evidence of treatment heterogeneity was seen for the effect of EPO on functional outcome.
CONCLUSION: EPO neither decreased overall long-term mortality nor improved functional outcome in moderate or severe TBI patients treated in the intensive care unit (ICU). The limited sample size makes it difficult to make final conclusions about the use of EPO in TBI.
参考来源
- Skrifvars MB, Luethi N, Bailey M, et al. The effect of recombinant erythropoietin on long-term outcome after moderate-to-severe traumatic brain injury. Intensive Care Med. 2023. PMID: 37405413. doi:10.1007/s00134-023-07141-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。